Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$33.00
▲(4.60% Upside)
Action:Reiterated
Date:06/30/26
STRO scores below average primarily due to weak financial fundamentals: persistent large losses, substantial cash burn, and negative equity increase funding/solvency risk. Technicals provide partial support as the stock trades above key moving averages, but momentum is only neutral. Valuation adds little support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Proprietary cell-free protein synthesis platform
A proprietary cell-free platform (XpressCF) is a durable competitive advantage: it accelerates protein engineering, reduces development cycle times, and can be licensed to partners. This supports recurring collaboration revenue and sticky technical differentiation over years.
Negative Factors
Severe cash burn and negative operating cash flow
Sustained large negative operating and free cash flows create ongoing financing needs. Over a 2-6 month horizon this raises dilution or financing risk, constrains R&D flexibility, and forces management to prioritize near-term partner financing or capital markets access over long-term program choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-free protein synthesis platform
A proprietary cell-free platform (XpressCF) is a durable competitive advantage: it accelerates protein engineering, reduces development cycle times, and can be licensed to partners. This supports recurring collaboration revenue and sticky technical differentiation over years.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$550.14M
Dividend YieldN/A
Average Volume (3M)987.85K
Price to Earnings (P/E)―
Beta (1Y)3.57
Revenue Growth49.94%
EPS Growth44.76%
CountryUS
Employees269
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-307.72
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit2.19
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$50.50Price Target Upside60.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-8.73
Revenue Forecast (FY)$45.06M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions lik...
How the Company Makes Money
Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
31
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.61M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 98.33M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -106.12M | -145.65M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -153.60M | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | ||||||
| Total Assets | 241.99M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 202.56M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 13.63M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 308.88M | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -66.89M | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | ||||||
| Free Cash Flow | -152.14M | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -151.61M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 16.01M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 103.05M | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Positive
31.55
Price Trends
32.19
Positive
27.20
Positive
18.78
Positive
Market Momentum
-0.21
Negative
52.63
Neutral
56.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Positive. The current price of 31.55 is above the 20-day moving average (MA) of 28.64, below the 50-day MA of 32.19, and above the 200-day MA of 18.78, indicating a bullish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 52.63 is Neutral, neither overbought nor oversold. The STOCH value of 56.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $41.93M | -0.95 | -136.08% | ― | -77.56% | -50.38% | |
54 Neutral | $43.33M | -0.96 | -170.86% | ― | -100.00% | 13.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $550.14M | -0.11 | 275.30% | ― | 49.94% | 44.76% | |
47 Neutral | $80.77M | -0.58 | -80.35% | ― | ― | 27.27% | |
42 Neutral | $17.49M | -0.30 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
STRO
Sutro Biopharma
33.20
26.40
388.24%
CRVO
CervoMed
3.10
-2.83
-47.72%
ACET
Adicet Bio
8.64
-1.14
-11.63%
INMB
Inmune Bio
1.63
-0.46
-22.01%
HOWL
Werewolf Therapeutics
0.36
-0.69
-65.81%
Sutro Biopharma Corporate Events
Executive/Board ChangesShareholder Meetings
Sutro Biopharma Shareholders Back Board, Pay and Auditor
Positive
Jun 8, 2026
On June 5, 2026, Sutro Biopharma held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors, Jane Chung, Connie Matsui, and James Panek, each to serve a three-year term ending at the 2029 Annual Meeting. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.